NCT07920783
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
StatusNot Yet Recruiting
PhasePhase 1
SponsorGan & Lee Pharmaceuticals.
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
The incidence of adverse events (AEs)
Timeframe: SAD:Baseline to Day14 MAD:Baseline to Day38 FE:Baseline to Day12
The incidence of serious adverse events (SAEs)
Timeframe: SAD:Baseline to Day14 MAD:Baseline to Day38 FE:Baseline to Day12
Secondary (16)
Changes in STAT6
Changes in TARC
Cmax
AUC0-t
AUC0-inf
Show 11 moreShow less
Tmax
λz
t1/2
CL/F
Vz/F
Changes in IgE
Cmax,ss
Cmin,ss
Cav,ss
AUC0-τ,ss
Tmax,ss
Arms and interventions
GLR2053 TabletsExperimental
Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of GLR2053.
PlaceboPlacebo comparator
Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of matched placebo.
Drugs: GLR2053 Tablets, Placebo
Sites
1 site in 1 country
- Beijing GoBroad HospitalBeijing, China